General Comments / Chat, page-11102

@JH888

The current missing link is awareness.

I think you overestimate the capacity of investors to understand scientific literature and awareness to learn, and underestimate your knowledge of this field relative to those same investors.

Conservatively, I estimate that I have put more than 1500 hours into researching this opportunity and done my best to share that research with all of you. If you have been following me for any length of time, then you can appreciate the enormity of the opportunity and the depth of research that supports Bisantrene. Anyone who has read the majority of my material is hundreds of hours ahead of anyone else. The time it takes to right long-form material for this forum is a small percentage of the time it has taken to collect all of the data.

I believe our time in the sun will come when it is obvious to the world that Bisantrene is a first-in-class opportunity, it always has been, and the market for such a drug is enormous and without clinical competition.